Abbott Laboratories Secures Major Acquisition Funding Amid Legal Headwinds

The healthcare giant Abbott Laboratories has taken a decisive step toward completing the largest acquisition in its corporate history. To finance the $21 billion purchase of diagnostics specialist Exact Sciences, the company has successfully issued $20 billion in senior notes. While this bold growth move is supported by solid financial forecasts, it is currently being overshadowed by significant product recalls and litigation, creating investor unease.

Financial Confidence and Shareholder Returns

Despite recent challenges, Abbott continues to project financial strength. Demonstrating its commitment to shareholders, the company announced its 54th consecutive annual dividend increase, raising the quarterly payout to $0.63 per share. Management’s outlook for the full year 2026 remains positive, forecasting organic sales growth between 6.5% and 7.5%. Adjusted earnings per share are projected to land in the range of $5.55 to $5.80.

A Transformative Deal Nears Completion

The financing secured through the bond placement finalizes the capital required for the transformative Exact Sciences deal. Shareholders had already granted their approval for the acquisition on February 20, with closure now scheduled for March 9, 2026. Post-acquisition, Exact Sciences will operate as a subsidiary, a move expected to substantially bolster Abbott’s footprint in the competitive diagnostics market.

Should investors sell immediately? Or is it worth buying Abbott Laboratories?

Legal and Operational Challenges Emerge

This aggressive expansion strategy is encountering turbulence. Abbott’s share price has recently exhibited volatility, currently trading at €97.59. Investor concern is primarily fueled by a Class I recall—the most serious type—for its key FreeStyle Libre product. The device has been associated with reports of injury and death. Compounding the issue, a new class-action lawsuit filed in California alleges the company knowingly sold defective sensors. These developments have dampened market sentiment, causing the stock to underperform the broader market.

A Critical Juncture Ahead

As the March 2026 acquisition deadline approaches, Abbott enters a pivotal period. The equity’s performance in the coming months will largely hinge on whether the anticipated synergies from integrating Exact Sciences can successfully offset the financial and reputational risks posed by the ongoing product liability lawsuits. The company’s ability to navigate these concurrent challenges will be closely watched by the investment community.